Crystal Pharmatech

Executive Summary

Crystal Pharmatech is a leading contract development and manufacturing organization (CDMO) specializing in solid-state research, crystallization, and formulation for small-molecule drugs. Founded in 2010 and headquartered in Newark, Delaware, the company offers integrated services from early-stage Mol2Med™ development to commercial GMP manufacturing, with a focus on de-risking development through its 'First-Time-Right' approach. Serving the pharmaceutical industry, Crystal Pharmatech leverages expertise in solid-state chemistry to accelerate drug development timelines and improve success rates. As a privately held, pre-clinical stage company with 201–500 employees, it is well-positioned to capture growing demand for specialized CDMO services in the small-molecule space.

Upcoming Catalysts (preview)

• Q3 2026Expansion of GMP Manufacturing Capacity70% success
• TBDStrategic Partnership or Licensing Deal50% success
• TBDKey Client Drug Milestone (e.g., IND Filing)40% success